Market Place
Sourcing Support
Ionis Antisense Drug Stabilizes Ultra-Rare Disease Before FDA
22 Apr 2026 //
BIOSPACE
European Union Approves DAWNZERA For Hereditary Angioedema
21 Jan 2026 //
BUSINESSWIRE
Ionis Ramps Up Angelman Syndrome Awareness With Lifetime Segment
17 Dec 2025 //
FIERCE PHARMA
Ionis Granted FDA Breakthrough Therapy Designation for AxD
02 Dec 2025 //
BUSINESSWIRE
Dawnzera Receives Positive Opinion from CHMP
15 Nov 2025 //
BUSINESSWIRE
Ionis Reveals Dawnzera`s Long-Term Disease Control At ACAAI
06 Nov 2025 //
BUSINESSWIRE
Ionis Rare Disease Candidate Ekes out Phase 3 Win
22 Sep 2025 //
FIERCE BIOTECH
Tryngolza (Olezarsen) Approved in EU for Chylomicronemia Syndrome
19 Sep 2025 //
PR NEWSWIRE
Trygolza Gets EU Approval for Chylomicronemia Syndrome
19 Sep 2025 //
BUSINESSWIRE
Ionis Gets FDA Breakthrough Designation for ION582 in Angelman
09 Sep 2025 //
BUSINESSWIRE
Ionis Picks Orsini as Sole Specialty Pharmacy for Dawnzera
25 Aug 2025 //
PR NEWSWIRE
FDA Gives Nod to 3rd HAE Drug, Ionis` Dawnzera, in 2 Months
23 Aug 2025 //
FIERCE PHARMA
Ionis CDO Dr Geary to Retire Dr Kordasiewicz Named Successor
12 Jun 2025 //
BUSINESSWIRE
First Patient Dosed in Ph 3 Study of ION582 in Angelman syndrome
11 Jun 2025 //
BUSINESSWIRE
Ionis chalks up phase 3 trial win as it works to grow Tryngolza
19 May 2025 //
FIERCE PHARMA
Ionis Sends Polycythemia Vera Drug to Ono in Deal Worth Nearly $1B
13 Mar 2025 //
BUSINESSWIRE
US FDA approves Ionis Pharma`s genetic disorder drug
20 Dec 2024 //
REUTERS
Zilganersen granted FDA Fast Track designation for Alexander disease
01 Oct 2024 //
PR NEWSWIRE
Ionis presents pivotal rare disease data, builds toward first solo launch
08 Apr 2024 //
PRESS RELEASE
Olezarsen receives Orphan Drug designation from U.S. FDA
15 Feb 2024 //
PRESS RELEASE
FDA approves AstraZeneca, Ionis treatment for rare nerve disease
22 Dec 2023 //
PRESS RELEASE
Otsuka pays Ionis $65M for European rights to rare disease drug
19 Dec 2023 //
FIERCE BIOTECH
Ionis chops two PhII programs in acromegaly and beta thalassemia
05 May 2023 //
ENDPTS
Ionis` midphase misses send rare disease prospects to the abyss
04 May 2023 //
FIERCE BIOTECH
Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs
25 Apr 2023 //
BIOPHARMADIVE
Did Novartis get $150M worth of positive PhII cardio data from Akcea?
14 Nov 2018 //
ENDPTS
An expensive new medication is finally available for her rare disease
10 Nov 2018 //
MARKET WATCH
Ionis may have found a home for dry AMD drug with Roche in $760M deal
10 Oct 2018 //
FIERCE BIOTECH
Akcea Therapeutics genetic disease treatment gets FDA approval
06 Oct 2018 //
REUTERS
FDA nixes Akcea’s volanesorsen despite favorable AdComm
28 Aug 2018 //
FIERCE BIOTECH
FDA rejects rare disease drug developed by Cambridge`s Akcea
28 Aug 2018 //
BIZ JOURNALS
FDA declines to approve Akcea-Ionis genetic disease drug
27 Aug 2018 //
REUTERS
IONIS-HTT Rx (RG6042) Granted PRIME Designation by the EMA
02 Aug 2018 //
PR NEWSWIRE
Akcea, PTC Therapeutics Collaborate on 2 Rare Disease Drugs in Latin America
02 Aug 2018 //
PR NEWSWIRE
With tech from Spinraza’s maker, French startup Dynacure gets $55M
06 Jul 2018 //
ENDPTS
Akcea, Ionis win over most FDA experts to their rare disease drug volanesorsen
11 May 2018 //
ENDPTS
